Immunoproteasome inhibitors have been shown to ameliorate symptoms in preclinical models of different autoimmune diseases [43, 44], and KZR-616, a drug targeting both PSMB8 and PSMB9, has been tested in a Phase II trial of systemic lupus erythematosus [45]. This evidence concerns the gene PSMB9 and systemic lupus erythematosus.